MedTrace Logo

Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis

NCT07746518 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-08-13

No results posted yet for this study

Summary

A Multi-center, Double-blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial and Open-label Extension Study to Evaluate the Efficacy and Safety of DWP14012 for Maintenance Therapy in Patients with Healed Erosive Esophagitis

Conditions

  • Healed Erosive Esophagitis

Interventions

DRUG

DWP14012 20mg

20mg, 1 tablet, Orally, Once a day

DRUG

DWP14012 20 mg placebo

1 tablet, Orally, Once a day

DRUG

DWC202517 15 mg

15mg, 1 capsule, Orally, Once a day

DRUG

DWC202517 15 mg placebo

1 capsule, Orally, Once a day

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-08-31
Completion
2030-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746518 on ClinicalTrials.gov